OYE Therapeutics

OYE Therapeutics is developing a novel injectable drug product aimed at revolutionizing the treatment of opioid overdose and reversing general anesthesia, two areas with significant unmet medical needs. The company positions its solution as addressing the shortcomings of naloxone, such as its short duration of action and high relapse rate, while also targeting a massive $95B annual cost burden associated with overdose treatment. As a private, pre-revenue, clinical-stage biotech, OYE is seeking investment to advance its lead candidate through development for multiple clinical settings including emergency departments, EMS, and surgical centers.

Novel injectable formulation platform designed for sustained reversal of opioid effects and general anesthesia, aiming to overcome the short duration of action and high relapse rates associated with current standard care (naloxone).

The overdose rescue market is dominated by naloxone (generic and branded Narcan). OYE's competition is the inadequacy of the current standard, not a direct equivalent novel agent. In anesthesia reversal, there is no approved drug, making it a greenfield opportunity but also requiring creation of a new standard of care.